TORNALATE
LOE ApproachingNDAINHALATIONSOLUTION
Approved
Feb 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TORNALATE is an inhaled small-molecule bronchodilator approved in 1992 for respiratory indications. The product is administered as an inhalation solution and works through an unknown mechanism of action. Specific therapeutic indications are not documented in available data.
LOE Approaching
Product is approaching loss of exclusivity with modest competitive pressure (30%), suggesting a contracting team and focus on generic transition management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TORNALATE represents a mature asset with zero linked job postings, indicating minimal hiring and limited career growth opportunities. Roles on this product focus on defending market share and managing the transition to generic competition.
Brand ManagerField Sales Representative
Worked on TORNALATE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.